Pulmonary arterial hypertension treatment. A new era

IF 1.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Sophia Anastasia Mouratoglou , Alexandra Arvanitaki , George Papadopoulos , Rogerio Souza , George Giannakoulas
{"title":"Pulmonary arterial hypertension treatment. A new era","authors":"Sophia Anastasia Mouratoglou ,&nbsp;Alexandra Arvanitaki ,&nbsp;George Papadopoulos ,&nbsp;Rogerio Souza ,&nbsp;George Giannakoulas","doi":"10.1016/j.ijcchd.2025.100594","DOIUrl":null,"url":null,"abstract":"<div><div>Pulmonary arterial hypertension (PAH) is a progressive and life-threatening condition characterized by elevated pulmonary vascular resistance, ultimately leading to right heart failure and death. Advances in the understanding of PAH pathophysiology have driven the development of targeted therapies that improve functional capacity, quality of life and survival. The current treatment paradigm emphasizes early and aggressive therapy, with combination therapy now considered standard of care, offering superior outcomes compared to monotherapy. Herewith, we examine the underlying pathophysiological mechanisms of PAH and explore the modes of action and clinical efficacy of major therapeutic classes, providing a comprehensive overview of contemporary treatment strategies.</div></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"21 ","pages":"Article 100594"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of cardiology. Congenital heart disease","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666668525000308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Pulmonary arterial hypertension (PAH) is a progressive and life-threatening condition characterized by elevated pulmonary vascular resistance, ultimately leading to right heart failure and death. Advances in the understanding of PAH pathophysiology have driven the development of targeted therapies that improve functional capacity, quality of life and survival. The current treatment paradigm emphasizes early and aggressive therapy, with combination therapy now considered standard of care, offering superior outcomes compared to monotherapy. Herewith, we examine the underlying pathophysiological mechanisms of PAH and explore the modes of action and clinical efficacy of major therapeutic classes, providing a comprehensive overview of contemporary treatment strategies.
肺动脉高压治疗。新时代
肺动脉高压(PAH)是一种进行性和危及生命的疾病,其特征是肺血管阻力升高,最终导致右心衰和死亡。对多环芳烃病理生理学的理解的进步推动了靶向治疗的发展,这些治疗可以改善功能能力、生活质量和生存率。目前的治疗模式强调早期和积极的治疗,与单一治疗相比,联合治疗现在被认为是标准治疗,提供了更好的结果。在此,我们研究了多环芳烃的潜在病理生理机制,并探讨了主要治疗类别的作用模式和临床疗效,提供了当代治疗策略的全面概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International journal of cardiology. Congenital heart disease
International journal of cardiology. Congenital heart disease Cardiology and Cardiovascular Medicine
自引率
0.00%
发文量
0
审稿时长
83 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信